Hosting Organization
Operating Organization


Foreign Experts Databank
of SAFEA-Dalian Biotechnological and Medical Experts Subdivision

BIT Lifesciences, Inc.
Supporting Organization
International Marketing Partner

Participants List
(Academia)

National Yang-Ming University, Taiwan

Abyad Medical Center and Middle-East Longevity Institute, Lebanon

Akershus University Hospital, Norway

Aligarh M University, India

American University of Beirut, USA

Antwerp University Hospital, Belgium

Applied Proteomics and Molecular Medicine, USA

Aristotelian University of Thessaloniki, Greece

Banaras Hindu University, India

Barrow Neurological Institute, USA

Baylor College of Medicine, USA

Ben-Gurion University of the Negev, Israel

Boston University School of Medicine, USA

Cancer Research Technology, UK

CHDI Foundation, California

Chinese Academy of Sciences, China

CRG-Centre de Regulaci Genmica, Spain

CSIRO Molecular and Health Technologies, Australia

Duke University, USA

Emory University, USA

exas Southern University, USA

Florida A&M University, USA

Global Pathology Support, The Netherlands

Gujarat AIDS Awareness and Prevention Unit, India

Haematopoietic Stem Cell Laboratory, UK

Harvard Medical School, USA

Hospital S Hospital S Joao, Portugal

Human BioMolecular Re-. search Institute, USA

Indiana University School of Medicine, USA

Indiana University School of Medicine, USA

Innsbruck Medical University, Austria

Institute of Experimental Pharmacology, Slovak

Instituto De Biologia Experimentale Tecnologica, Portugal

Karolinska Institutet, Sweden

Keystone College Academia, USA

McGill University, Canada

Mercer University, USA

National Center for Toxicological Research, USA

National Institutes of Health, USA

Netherlands Cancer Institute, The Netherlands
New York Medical College, USA

Osaka University, Japan

Paul-Ehrlich-Institute, Germany

Penn State College of Medicine, USA

Pennsylvania State University College of Medicine, USA

Pharmacology Temple University, USA

Scientific Advisory Board Tolerx, USA 

Shanghai Unviversity of Traditional Chinese Medicine, China

Solid Tumor Working Party, Italy

Stanford University, USA

Structural Genomics Consortium Karolinska Institutet, Sweden

Tabriz University of Medical Sciences, Iran

Technion - Israel Institute of Technology Rappaport Institute, Israel

The Babraham Institute, UK

The Hebrew University, Israel

The Institute of Cancer Research, UK

The University of Queensland, Australia

The University of Sydney, Australia

The University of Texas, USA

UC College of Medicine, USA

Universidade Federal Fluminense, Brazil

University Clinic Bonn, Germany

University of Basel, Switzerland

University of British Columbia, Canada

University of California, USA

University of California-San Francisco, USA

University of Camerino, Italy

University of Cape Town, USA

University of Colorado Health Sciences Center, USA

University of Crete, Greece

University of Geneva, Switzerland

University of Heidelberg, Germany

University of Hong Kong, China

University of Maryland School of Pharmacy, USA

University of Maryland, USA

University of Massachusetts Medical School, USA

University of Miami School of Medicine, USA

University of Miami, USA

University of Miami, USA

University of Oklahoma Health Sciences Center, USA

University of Siena, Italy

University of Southern Denmark, Denmark

University of Texas at Dallas, USA

University of Texas Health Science Center, USA

University of Texas Medical, USA

University of the Sciences in Philadelphia, USA

University of Utah School of Medicine, USA

University of Western Australia, Australia

Utah State University, USA

Virginia Commonwealth University, USA

University of Gothenburg, Sweden


Participants List
(Business)

3 P Biopharmaceuticals, USA

Abbott Laboratories, USA

Adolor Corporation, USA

Affimed Therapeutics AG, Germany

AILERON Therapeutics, USA

Algorithme Pharma Inc., Canada

Allon Therapeutics Inc., USA

Alpha Cancer Technologies Inc., USA

Alpha-2 Pharmaceutica AB, Israel

Amgen, Inc., USA

Arena Pharmaceuticals, USA

Astellas Pharma Inc, Japan

Astellas Pharmaceutical Inc., Japan

AstraZeneca Pharmaceuticals, USA

AstraZeneca R&D Molndal, Sweden

Astrazeneca R&D Sodertolje, Sweden

AstraZeneca, UK

AstraZeneca, USA

AuxoCell Laboratories, Inc., USA

Avexa Ltd, Australia

Bayer HealthCare, USA

Bayer Schering Pharma AG, Germany

BellBrook Labs, LLC, USA

Biological Mimetics, Inc., USA

BioPerspectives, USA

Biota Holdings Limited, USA

Boehringer Ingelheim Pharmaceuticals, Inc., USA

Bristol-Myers Squibbs, USA

Centocor/Johnson & Johnson, USA

Chemistry Forma Therapeutics, Inc., Singapore

Coley Pharmaceutical GmbH, Germany

Cordex Pharma, Inc., USA

Cornerstone Pharmaceuticals, USA

Covidien, USA

Daiichi Sankyo Pharma Development, Japan

deCODE Chemistry, USA

DxS Ltd, USA

Eisai Co., Ltd., Japan

Elan Pharmaceuticals, USA

Europe GlaxoSmithKline R&D, UK

Genentech, USA

Genetix Ltd, UK

genscript, USA

Genzyme Pharmaceuticals, USA

Gilead Sciences Benzothiadiazine Hepatitis C NS5B, USA

Hoffmann-La Roche, Switzerland
ICON PLC, USA

IDDC Corporation, USA

Idera Pharmaceuticals, USA

Jesus College, England

Johnson & Johnson Pharmaceutical, USA

Johnson & Johnson Research Pty Limited, Australia

Laboratory Cellular Technology Ltd., USA

Lundbeck Research, USA

Mallinckrodt, Inc., USA

MDS Pharma Services, USA

Medimmune, UK

Merck & Co. Inc, USA

Merck & Co., Italy

Merck and Co., Inc., China

Merck KGaA, Germany

Merck Research Laboratories, USA

Nerviano Medical Sciences, Italy

Novartis Institutes for Biomedical Research, USA

Novartis Institutes, Switzerland

Novartis Pharmaceuticals Corporation, USA

Novartis, China

Ocimum Biosolutions, India

Ondokuz Mayis University, Turkey

OphthalmoPharma, Switzerland
Pfizer, USA

Pharmanet Development Group, Inc., USA

PharmaNet, Inc., USA

Ranbaxy Laboratories Limited, India

Reaction Biology Corporation, USA

RegPak BioPharma Consulting, The Netherlands

Sanofi Aventis, USA

Schering Plough Research Institute, USA

Schlich & Co, UK

Scott & White, USA

Sequoia Pharmaceuticals Inc., USA

SeraCare Life Sciences, USA

Shanghai Biochip Co., Ltd, China

Shenogen Pharma Group, China

Siena Biotech S.p.A. A company, USA

Simulations Plus, Inc., USA

Synta Pharmaceuticals Corp, USA

TEVA Pharmaceuticals, USA

The Takeda Oncology Company, USA

ThromboGenics, USA

Transgene, France

US Oncology Research, Inc., USA

Vaxinnate, USA

Wyeth Research, USA 

XOMA (US) LLC, USA

Zeptosens C a Division of Bayer (Schweiz) AG, Switzerland

Zhejiang Hisun Pharmaceutical Co., Ltd, China

Tehran University of Medical Sciences , Iran


CMBF 2009
(Aug. 8-10, 2009, Dalian, China)
RMSC 2009
(Aug. 8-10, 2009, Dalian, China)
IDDST 2009
(Oct.22-25, 2009, Shanghai, China)
 
CEMD 2009
(Nov.19-21, 2009, Beijing, China)
WCG 2009
(December 1-7, 2009, Foshan, China)
 
ICC 2009
(Dec. 5-7, 2009, Shanghai, China)
Pepcon 2010
(March 21-23, 2010, Beijing, China)
ICA 2010
(March 24-26, 2010, Beijing, China)
WCV 2010
(March 24-26, 2010, Beijing, China)
SEB 2010
(Apr. 22-24, 2010, Shanghai, China)
WCC-Breast Cancer 2010
Tri-Breast Cancer Conference

(Apr. 25-27, 2010, Shanghai, China)
WCIT 2010
(May 15-18, 2010, Beijing, China)
ICM 2010
(May 18-20, 2010, Beijing, China)
WCCAS 2010
(May 19-21, 2010, Beijing, China )
IBIO 2010
(July 25-27, 2010, Qingdao, China)
WCVI-2010
(July 31-August 3, 2010, Korea)
 
 Schedule

IDDST 2009 is comprised of Eight Section s designed to offer comprehensive sessions that address current issues in Drug R&D and innovative therapeutics. You can register a whole conference or select a single Section or register for special service package that you want for your participation. Now the program is under developing from viewing submitted abstracts.

Chapter 1: Basic Sciences of Preclinical Studies
-Sciences is All We Need to Start

Chapter 2: Smart Drug Discovery Chemistry
-Applied Robust Chemistry to Better Molecules

Chapter 3: Methodology & Innovative tools for drug discovery, Drug delivery and Drug Development
-Master the Matured Cutting-Edge Technologies for Drug Innovations

Chapter 4: Translational Medicine
-Bridge Pharm R & D from Bench to Bedside

Chapter 5: Drug Discovery of Major Diseases
-Targeting Unsolved Life Threatening Diseases

Chapter 6: New Heats for Biotherapeutics
-Discover Humanized Natural Bio-Drugs

Chapter 7: Milestones of Novel Therapeutics Pipeline
-Update and Case Studies for Novel INDs on Trials

Chapter 8: Outsourcing, Partnership, and Licensing across the World
- Cost Effective and Result Driving Forces

Program Schedule

Time: October 22-25 Venue: Everbright Convention and Exhibition Center , Shanghai , China 

Time

Program

Place

October 21, 2009 (Wednesday)
08:00-20:00

Registration

Lobby, 1F, ECEC

October 22, 2009 (Thursday)
08:20-08:40

Group Photo

The Gate of ECEC, 1F

October 22, 2009 (Thursday)
09:00-09:35

Opening Ceremony

Grand Ball, 2F, ECEC

October 22, 2009 (Thursday)
09:40-11:45

Keynote Forum

October 22, 2009 (Thursday)
18:30-20:30

Welcome Banquet and Art Performance (Sponsored by Roche)

 

October 22, 2009 (Thursday) Afternoon

13:30-17:50

Section 1-1: Oncology and Drug Discovery

Room No. 9, 2F, ECEC

15:05-17:35

Section 1-2: Inflammation and Drug Discovery

Room No. 16, 2F, ECEC

13:30-17:30

Section 2-1: Receptors and Ion Channel Based Drug Design and Development

Room No. 18, 2F, ECEC

13:30-16:45

Section 2-2: Fragment Based Drug Design and Development

Room No. 20, 2F, ECEC

13:30-16:50

Section 3-1: Functional Genomics, Proteomics, Metabolomics, System Biology for Drug Discovery

Room No. 11, 2F, ECEC

13:30-16:50

Section 3-2: Molecular Target and Biomarkers for Drug Discovery

Room No. 12, 2F, ECEC

13:30-17:50

Section 3-13: Current Strategies of Bioequivalence & Bioavailability in Drug Development (Sponsored by OMICS Publishing Group)

Room No.8, 2F, ECEC

13:30-14:45

Section 4-1: Translational Biomedicine and Multiplex Assays for the Progress of Translational Medicine

Room No. 16, 2F, ECEC

13:30-17:10

Section 5-1: Anticancer Drug Discovery (Part I)

Room No. 7, 2F, ECEC

October 23, 2009 (Friday) Morning

08:10-12:30

Section 1-3: Endocrinology and Drug Discovery

Room No. 7, 2F, ECEC

08:30-11:45

Section 1-4: Immunology and Drug Discovery

Room No. 11, 2F, ECEC

08:10-10:10

Section 2-3: RNA/DNA Structure-Based Drug Discovery Chemistry

Room No. 12, 2F, ECEC

08:30-11:50

Section 2-4: Computer Aided Drug Design and SAR Studies

Room No. 16, 2F, ECEC

10:30-12:10

Section 3-3: Biochips, Microarray and Molecular Imaging for Drug Discovery

Room No. 12, 2F, ECEC

08:10-10:10

Section 3-4: Bioinformatics/Chemoinformatics and Bio-IT/Pharm-IT for Drug Discovery

Room No. 9, 2F, ECEC

08:30-11:50

Section 4-2: Translational Medicine from Biomarkers, Molecular Profiling to Clinical Trials

Room No. 20, 2F, ECEC

10:30-12:10

Section 5-3: Anti-Neurodegenerative Drug Discovery

Room No. 9, 2F, ECEC

08:30-11:45

Section 5-4: Cardiovascular & Pulmonary Diseases and Drug Discovery

Room No. 18, 2F, ECEC

08:30-12:10

Section 6-2: Monoclonal Antibody Based Biotherapeutics

Room No. 8, 2F, ECEC

October 23, 2009 (Friday) Afternoon

13:30-15:10

Section 1-5: Pharmacology, PK/PD and Drug Discovery

Room No. 8, 2F, ECEC

15:30-17:30

Section 1-6: Toxicology and Drug Discovery

Room No. 18, 2F, ECEC

13:30-15:10

Section 2-5: Virtual Screening to Combinatorial Chemistry for Hit Findings

Room No. 12, 2F, ECEC

13:30-16:45

Section 2-6: Structure Biology Based Drug Design and Synthesis

Room No. 7, 2F, ECEC

15:30-17:00

Section 3-5: RNAi, microRNA, and Non-Coding RNA Technologies

Room No. 12, 2F, ECEC

13:30-17:10

Section 3-12: Pharmaceutical Analysis and Quality

Room No. 11, 2F, ECEC

15:30-17:30

Section 5-5: Anti-inflammation and Anti-autoimmune Diseases Drug Discovery

Room No. 8, 2F, ECEC

13:30-17:10

Section 6-1: Protein Based Biotherapeutics

Room No. 16, 2F, ECEC

15:30-17:00

Section 6-3: Gene Therapeutics R & D

Room No. 20, 2F, ECEC

13:10-15:10

Section 7-1: Anticancer Pipeline Therapeutics

Room No. 18, 2F, ECEC

13:30-15:10

Section 8-2: Services in Biological Sciences

Room No. 20, 2F, ECEC

13:30-17:10

Satellite Symposium: Emerging Approaches to Improve Medicine (Sponsored by Roche Applied Science)

Room No. 9, 2F, ECEC

October 23, 2009 (Friday) Evening

18:00-20:00

Cocktail Party (Sponsored by Viva Biotech Ltd. )

 

October 24, 2009 (Saturday) Morning

08:30-12:10

Section 1-7: Molecular/Cell Biology and Drug Discovery

Room No. 18, 2F, ECEC

08:10-10:10

Section 1-8: Neurology and Drug Discovery

Room No. 7, 2F, ECE

08:30-10:10

Section 2-7: Novel Methods for Lead Modification

Room No. 20, 2F, ECEC

10:30-12:10

Section 2-8: Organometallic Chemistry in Drug Development

08:30-12:10

Section 3-7: Cell-based to Tissue-based Assays

Room No. 9, 2F, ECEC

09:50-12:30

Section 3-14: Recent Advances in Drug and Gene Delivery

Room No. 11, 2F, ECEC

08:30-12:10

Section 5-6: Anti-Bacterial & Antifungal Drug Discovery (Part I)

Room No. 12, 2F, ECEC

08:20-11:30

Section 6-4: Cell Therapeutics and Regenerative Medicine

Room No. 16, 2F, ECEC

08:10-09:30

Section 7-2: Anti-Infectious Therapeutics

Room No. 11, 2F, ECEC

10:30-12:30

Section 7-3: Anti-Diabetes Therapeutics

Room No. 7, 2F, ECE

08:30-12:10

Section 8-1: Integrated Services & Partnership for Drug Discovery (Part I)

Room No. 8, 2F, ECEC

October 24, 2009 (Saturday) Afternoon

13:30-16:45

Section 1-9: Microbiology, Virology and Drug Discovery

Room No. 7, 2F, ECEC

15:30-17:50

Section 1-10: Hematology and Drug Discovery

Room No. 11, 2F, ECEC

13:30-16:45

Section 3-6: Cardiotoxicity / Hepatotoxicity and Drug Safety

Room No. 20, 2F, ECEC

13:30-15:10

Section 3-8: High Content Imaging (Sponsored by PerkinElmer Instruments ( Shanghai ) Co. Ltd)

Room No. 11, 2F, ECEC

13:30-17:10

Section 4-3: Translational Oncology

Room No. 12, 2F, ECEC

13:30-17:10

Section 5-2: Anti-Diabetes Drug Discovery

Room No. 9, 2F, ECEC

13:30-17:20

Section 5-7: Anti-Bacterial & Antifungal Drug Discovery (Part II)

Room No. 16, 2F, ECEC

13:30-17:30

Section 7-4: Anti-CNS Disorder Therapeutics

Room No. 18, 2F, ECEC

13:30-17:30

Section 8-4: Integrated Services & Partnership for Drug Discovery (Part II)

Room No. 8, 2F, ECEC

October 25, 2009 (Sunday) Morning

08:30-11:45

Section 2-9: Improving ADME/DMPK Profile, Reducing DDI/Toxicity, and Overcoming Formulation Difficulties

Room No. 18, 2F, ECEC

08:30-12:10

Section 3-9: In Silico Models and Model Systems

Room No. 12, 2F, ECEC

08:30-12:10

Section 3-10: Nanotechnology and Novel Drug Delivery

Room No. 11, 2F, ECEC

08:30-11:40

Section 3-11: HPLC, LC-MS, Maldi-TOF and Structure Biology for Drug Discovery

Room No. 16, 2F, ECEC

08:30-10:10

Section 4-4: Translational Neurosciences

Room No. 7, 2F, ECEC

08:30-09:45

Section 5-8: Anti-HIV Drug Discovery

Room No. 20, 2F, ECEC

10:05-12:10

Section 5-9: Anti-HCV Drug Discovery

Room No. 20, 2F, ECEC

10:30-12:10

Section 5-10: Gastrointestinal Drug Discoveries

Room No. 7, 2F, ECEC

08:30-12:10

Section 5-11: Anticancer Drug Discovery (Part II)

Room No. 9, 2F, ECEC

08:10-12:15

Section 8-3: PK/PD and Bioanalysis Outsourcing Alliance

Room No. 8, 2F, ECEC

10/26-10/27/2009 (Monday, Tuesday)

Tech Tour

Hangzhou and Suzhou


BIT' s Claims: All events BIT Life Sciences organized are purely for promotion of advancement of sciences and technologies for the sustainable development of a healthier and wealthier world. No political, religious racial bias and non-ethic knowledge are accepted through our intelligence exchange platform. Any illegal and offensive Information will be 100% avoided.